New study identifies key cells that may help develop drugs to prompt patients' own endothelial cells to regenerate and grow new blood vessels. Such therapies can potentially benefit people with heart disease and peripheral vascular disease.
New study identifies key cells that may help develop drugs to prompt patients' own endothelial cells to regenerate and grow new blood vessels. Such therapies can potentially benefit people with heart disease and peripheral vascular disease, reports a new study. The findings of the study are published in the European Heart Journal. Therapies to improve recovery after a heart attack could be developed following fresh insights into how key cells are formed.
‘Blood supply treatment boosted fresh insights into key cells that may help people with heart disease and other conditions that affect the blood supply, such as peripheral vascular disease.’
Scientists have developed a system that allows them to study cells that line the walls of blood vessels, called endothelial cells.Researchers say the findings shed light on how the cells can be best grown in the lab for use as therapies. They could also help develop drugs to prompt patients' own endothelial cells to regenerate and grow new blood vessels.
Such treatments could potentially help people with heart disease and other conditions that affect the blood supply, such as peripheral vascular disease - a disorder that can lead to the loss of lower limbs.
Endothelial cells are vital to the process of supplying blood to damaged tissue following a heart attack. The team at the University of Edinburgh studied embryonic stem cells - early-stage cells that are not yet developed - and turned them into endothelial cells in the lab.
They used advanced techniques to visualize the genes that are turned on or off in individual cells as they undergo the transition to becoming endothelial cells.
Advertisement
The research was led by the British Heart Foundation Centre for Cardiovascular Science at the University of Edinburgh and is published in the European Heart Journal. It was funded by the Medical Research Council, Wellcome, the European Research Council and the British Heart Foundation.
Advertisement
Source-Eurekalert